Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study

Purpose Severe adverse events frequently occur in patients treated with sorafenib, whereas some patients have suboptimal response to sorafenib. We aimed to evaluate the association of sorafenib-induced toxicities and clinical outcomes with the pharmacokinetics of sorafenib in patients with hepatocel...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2020-07, Vol.86 (1), p.129-139
Hauptverfasser:	Noda, Satoshi, Hira, Daiki, Osaki, Rie, Fujimoto, Takehide, Iida, Hiroya, Tanaka-Mizuno, Sachiko, Andoh, Akira, Tani, Masaji, Ikeda, Yoshito, Morita, Shin-ya, Terada, Tomohiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic Agents - adverse effects Antineoplastic Agents - blood Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Cancer Research Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - mortality Confidence intervals Female Hepatocellular carcinoma Humans Inhibitor drugs Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - mortality Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Patients Pharmacokinetics Pharmacology/Toxicology Quality Retrospective Studies Sorafenib - adverse effects Sorafenib - blood Sorafenib - pharmacokinetics Sorafenib - therapeutic use Targeted cancer therapy Toxicity Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!